Topic starter
There is a new scientific article which for the first time directly compares the acute effects of MDMA and MDA, along with two experimental prodrug variants.
In it, we discuss:
The researchers conducted a double-blind, randomised, placebo-controlled crossover study in 23 healthy participants. Over five test days, they received placebo, 100 mg MDMA, 92 mg MDA, 172 mg lysine-MDMA or 164 mg lysine-MDA, all in equimolar doses. The researchers then looked at subjective effects, physical reactions, hormone changes and pharmacokinetics.
The real focus of this article is not on therapy results in patients, but on how MDMA, MDA and their prodrugs acutely differentiate from each other. This is relevant because MDMA is already being studied therapeutically, while MDA is an active metabolite of MDMA and may have more psychedelic and stimulant effects.
The results show that both MDMA and MDA gave clear subjective and autonomic effects compared to placebo. In doing so, MDA was found to have stronger and longer effects than MDMA. The duration of the subjective feeling of a drug effect was on average 6.1 hours with MDA versus 4.1 hours with MDMA. In addition, MDA caused more stimulant effects, more unpleasant or negative drug effects, more anxiety and more visual changes.
It is also interesting that lysine-MDA did act as a kind of slow-release prodrug. Compared to regular MDA, lysine-MDA caused a slower onset and a later peak effect, while the other effects remained largely similar. For lysine-MDMA, this turned out differently. After administration, no MDMA was found in the blood, nor were corresponding subjective or autonomic effects seen. Thus, according to the authors, lysine-MDMA does not act as a functional prodrug of MDMA.
The pharmacokinetic data further show that the plasma half-life of MDMA was on average 7.3 hours and that of MDA 8.4 hours. This fits with the observation that MDA remained active longer. The authors therefore conclude that MDA has a less favourable therapeutic profile than MDMA, and that lysine coupling may alter the timing of effects but does not automatically improve tolerability.
Importantly, however, this study was done in healthy volunteers in an experimental setting. So this article says nothing about clinical effectiveness in PTSD or other conditions, but mainly something about differences in acute action, side effects and pharmacokinetics.
In one sentence, this article shows that MDA works longer, stronger and more psychedelic than MDMA, but also produces more adverse effects, while lysine-MDA slows down the effects and lysine-MDMA does not seem to work well at all as a prodrug.
Spoiler
New article description
Abstract
3,4-Methylenedioxymethamphetamine (MDMA) is used recreationally, as a research tool, and in MDMA-assisted therapy in patients with post-traumatic stress disorder. 3,4-Methylenedioxyamphetamine (MDA) is a psychoactive metabolite of MDMA. Acute effects of MDMA and MDA have never been directly compared in humans. Lysine-conjugated amphetamines slowly release active amphetamine once absorbed, suggesting pharmaceutical strategies to enhance tolerability and reduce abuse potential. Therefore, lysine-MDMA (Lys-MDMA) and lysine-MDA (Lys-MDA) were developed as prodrugs of MDMA and MDA, respectively. We used a double-blind, randomised, placebo-controlled, crossover design to compare acute responses to MDMA (100 mg), MDA (92 mg), Lys-MDMA (172 mg), and Lys-MDA (164 mg) at equimolar doses and placebo in 23 healthy participants (12 women, 11 men). Outcome measures included acute subjective, autonomic, and endocrine effects and pharmacokinetics. Compared with placebo, MDMA and MDA produced pronounced subjective and autonomic effects. After Lys-MDMA administration, no MDMA was detected in blood samples, and no corresponding subjective or autonomic effects were observed. MDA produced stronger and longer-lasting subjective “any drug effects” compared with MDMA, with effect durations of (mean ± SEM) 6.1 ± 0.5 vs 4.1 ± 0.4 h, respectively. Additionally, compared with MDMA, MDA induced greater subjective “stimulant effects,” more negative “bad drug effects,” more “fear,” and more “visual alterations.” Lys-MDA, compared with MDA, showed longer times to onset and maximal effect (1.1 ± 0.2 h and 3.0 ± 0.4 h vs. 0.7 ± 0.1 h and 2.0 ± 0.1 h) but otherwise induced similar effects. The plasma elimination half-lives (geometric mean) of MDMA and MDA were 7.3 and 8.4 h, respectively. In summary, MDA produced longer-lasting, stronger, more psychedelic-like perceptual acute effects and more adverse effects compared with MDMA when administered at equimolar doses. Lys-MDA represents a functional slow-release prodrug form of MDA, delaying both the onset and peak of subjective effects. In contrast, Lys-MDMA did not release MDMA, likely because of its tertiary amine structure, and thus does not represent a functional prodrug of MDMA. These results highlight MDA's less favourable therapeutic profile relative to MDMA and identify lysine conjugation as a potential strategy for modulating, but not necessarily improving, the tolerability of its effects. Trial registration: ClinicalTrials.gov identifier: NCT04847206.
Keywords: MDMA; MDA; lysine-MDMA; lysine-MDA; prodrug; pharmacokinetics; crossover trial; healthy participants.
Posted : 18 March 2026 14:54